Show simple item record

dc.contributor.authorLalatsa, A.
dc.contributor.authorGarrett, N. L.
dc.contributor.authorFerrarelli, T.
dc.contributor.authorMoger, J.
dc.contributor.authorSchaetzlein, A. G.
dc.contributor.authorUchegbu, I. F.
dc.date.accessioned2013-01-11T13:59:11Z
dc.date.available2013-01-11T13:59:11Z
dc.date.issued2012-06
dc.identifier.citationLalatsa , A , Garrett , N L , Ferrarelli , T , Moger , J , Schaetzlein , A G & Uchegbu , I F 2012 , ' Delivery of Peptides to the Blood and Brain after Oral Uptake of Quaternary Ammonium Palmitoyl Glycol Chitosan Nanoparticles ' , Molecular Pharmaceutics , vol. 9 , no. 6 , pp. 1764-1774 . https://doi.org/10.1021/mp300068j
dc.identifier.issn1543-8384
dc.identifier.otherPURE: 1268248
dc.identifier.otherPURE UUID: 1dff69bd-61fc-4864-9495-a5bf7f52d79b
dc.identifier.otherWOS: 000304728700022
dc.identifier.otherScopus: 84862015268
dc.identifier.urihttp://hdl.handle.net/2299/9582
dc.description.abstractThe clinical development of therapeutic peptides has been restricted to peptides for non-CNS diseases and parenteral dosage forms due to the poor permeation of peptides across the gastrointestinal mucosa and the blood-brain barrier. Quaternary ammonium palmitoyl glycol chitosan (GCPQ) nanoparticles facilitate the brain delivery of orally administered peptides such as leucine(5)-enkephalin, and here we examine the mechanism of GCPQ facilitated oral peptide absorption and brain delivery. By analyzing the oral biodistribution of radiolabeled GCPQ nanoparticles, the oral biodistribution of the model peptide leucine(5)-enkephalin and coherent anti-Stokes Raman scattering microscopy tissue images after an oral dose of deuterated GCPQ nanoparticles, we have established a number of facts. Although 85-90% of orally administered GCPQ nanoparticles are not absorbed from the gastrointestinal tract, a peak level of 2-3% of the oral GCPQ dose is detected in the blood 30 min after dosing, and these GCPQ particles appear to transport the peptides to the blood. Additionally, although peptide loaded nanoparticles from low (6 kDa) and high (50 kDa) molecular weight GCPQ are taken up by enterocytes, polymer particles with a polymer molecular weight greater than 6 kDa are required to facilitate peptide delivery to the brain after oral administration. By examining our current and previous data, we conclude that GCPQ particles facilitate oral peptide absorption by protecting the peptide from gastrointestinal degradation, adhering to the mucus to increase the drug gut residence time and transporting GCPQ associated peptide across the enterocytes and to the systemic circulation, enabling the GCPQ stabilized peptide to be transported to the brain. Orally administered GCPQ particles are also circulated from the gastrointestinal tract to the liver and onward to the gall bladder, presumably for final transport back to the gastrointestinal tract.en
dc.format.extent11
dc.language.isoeng
dc.relation.ispartofMolecular Pharmaceutics
dc.titleDelivery of Peptides to the Blood and Brain after Oral Uptake of Quaternary Ammonium Palmitoyl Glycol Chitosan Nanoparticlesen
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionNanopharmaceutics
dc.contributor.institutionPharmaceutics
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1021/mp300068j
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record